What is HC Wainwright’s Estimate for ATXS FY2024 Earnings?

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Research analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Astria Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings of ($1.74) per share for the year, up from their previous estimate of ($1.82). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q4 2024 earnings at ($0.50) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($1.88) EPS, FY2027 earnings at ($1.93) EPS and FY2028 earnings at ($1.62) EPS.

Several other equities analysts have also recently issued reports on ATXS. Oppenheimer raised their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Wedbush reiterated an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Finally, TD Cowen assumed coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They issued a “buy” rating and a $35.00 target price on the stock. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Astria Therapeutics currently has a consensus rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Stock Up 6.4 %

Shares of Astria Therapeutics stock opened at $9.75 on Monday. The business has a 50-day moving average price of $11.33 and a 200 day moving average price of $10.62. Astria Therapeutics has a fifty-two week low of $4.41 and a fifty-two week high of $16.90. The firm has a market cap of $550.19 million, a P/E ratio of -4.67 and a beta of 0.71.

Hedge Funds Weigh In On Astria Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ATXS. Barclays PLC increased its position in Astria Therapeutics by 70.5% in the 3rd quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock valued at $1,020,000 after acquiring an additional 38,321 shares during the period. Wellington Management Group LLP grew its stake in shares of Astria Therapeutics by 8.7% in the third quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock worth $1,624,000 after purchasing an additional 11,763 shares in the last quarter. RA Capital Management L.P. grew its stake in shares of Astria Therapeutics by 1.2% in the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after purchasing an additional 61,457 shares in the last quarter. Redmile Group LLC acquired a new position in shares of Astria Therapeutics during the third quarter valued at $3,423,000. Finally, Patient Square Capital LP bought a new stake in shares of Astria Therapeutics during the third quarter valued at about $434,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.